Subsequent Event |
3 Months Ended |
|---|---|
Mar. 29, 2026 | |
| Subsequent Events [Abstract] | |
| Subsequent Event | Subsequent Event On April 17, 2026, the Company acquired all of the issued share capital of LEX Diagnostics Limited (“LEX Diagnostics”), a privately held company, for cash consideration of approximately $100 million. The purchase price is subject to certain adjustments, including (i) indebtedness, (ii) working capital, and (iii) potential earn-out payments of up to $35 million, equal to 5% of the net revenue during the earn-out period from April 1, 2029 to March 31, 2035. LEX Diagnostics is a molecular diagnostics company developing products designed to enhance patient care by delivering clinical insights within minutes and at the time they are most valuable.
|